Revance Therapeutics, Inc.
$ 3.65
0.00%
17 Apr - close price
- Market Cap 381,024,000 USD
- Current Price $ 3.65
- High / Low $ 3.65 / 3.65
- Stock P/E N/A
- Book Value -1.55
- EPS -3.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -20.97 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Analyst Target Price
$9.47
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-04 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 | 2022-11-08 | 2022-08-09 | 2022-05-10 | 2022-02-28 |
| Reported EPS | -0.37 | -0.36 | -0.58 | -0.62 | -1.63 | -0.8 | -0.74 | -0.95 | -1.17 | -0.88 | -0.94 | -0.93 |
| Estimated EPS | -0.38 | -0.53 | -0.75 | -0.72 | -0.85 | -0.78 | -0.7 | -0.95 | -0.89 | -0.86 | -0.83 | -1 |
| Surprise | 0.01 | 0.17 | 0.17 | 0.1 | -0.78 | -0.02 | -0.04 | 0 | -0.28 | -0.02 | -0.11 | 0.07 |
| Surprise Percentage | 2.6316% | 32.0755% | 22.6667% | 13.8889% | -91.7647% | -2.5641% | -5.7143% | 0% | -31.4607% | -2.3256% | -13.253% | 7% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVNC
2026-03-28 16:30:27
The U.S. hyaluronic acid based dermal fillers market, valued at USD 1.53 billion in 2022, is projected to grow at a CAGR of 8.2% during the forecast period due to increasing awareness of cosmetic procedures and growing per capita income. Key factors driving market growth include the rising demand for minimally invasive cosmetic procedures among young people and the aging population, coupled with continuous product innovation and FDA approvals. However, the market faces restraints from the availability of alternative dermal fillers and concerns about temporary results or side effects.
2026-02-27 06:52:00
Revance has launched its new StriVectin Barrier Restore+ Collection, which includes the Barrier Restore+ Soothing Ceramide Cream and Barrier Restore+ Soothing Milky Mist. This fragrance-free, sensitive skin line is designed to strengthen the skin barrier, soothe irritation, and address visible signs of aging. The products feature the new Turmeric-146 Peptide™ and StriVectin's proprietary NIA-114® technology, aiming to provide clinically proven results for sensitive skin.
2026-02-26 23:09:41
Revance has launched its new StriVectin Barrier Restore+ Collection, featuring the Barrier Restore+ Soothing Ceramide Cream and Barrier Restore+ Soothing Milky Mist. This fragrance-free, sensitive skin line is clinically proven to strengthen the skin barrier, reduce redness, and address visible signs of aging. The products utilize new Turmeric-146 Peptide and StriVectin’s NIA-114® technology to help visibly improve skin health and appearance.
2026-02-21 21:55:09
Revance has initiated a price reduction for its botulinum toxin treatment, Daxxify, in an effort to better compete with AbbVie's market-leading Botox, after struggling with its initial premium pricing strategy. Despite an initial drop in Revance's share price, analysts view this move positively, as the company aims to accelerate market expansion and increase Daxxify sales, noting encouraging early results in account orders. The company also expects to launch Daxxify for cervical dystonia following recent FDA approval, aiming to capitalize on a rapidly growing market.
2026-02-05 21:29:36
Revance Therapeutics, Inc. (RVNC) has been acquired by Crown Laboratories, Inc. through a cash tender offer and second-step merger. Following the acquisition, RVNC common stock will be delisted from NASDAQ, transitioning it into a historical ticker symbol. The article details Revance's business focus on aesthetic and therapeutic offerings, its product portfolio including DAXXIFY and RHA Collection, and its key partnerships and financial highlights leading up to the acquisition.
2026-01-12 13:58:46
Revance, a global leader in aesthetics and skincare, has appointed Steve Kreider as EVP, Chief Revenue Officer – Aesthetics and Therapeutics. In this new role, Kreider will oversee Revance's U.S. sales and revenue strategy across both its Aesthetics and Therapeutics businesses to drive sustainable growth and enhance provider engagement. This appointment aims to strengthen the company's commercial execution and expand its market impact.
